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Background: Ursodeoxycholic acid is used in human medicine for litholytic manage-
ment of choleliths, but the efficacy of medical management in dogs with cholelithiasis
is unknown.
Objectives: To describe the clinical features and outcomes of dogs with cholelithiasis,
focusing on cases that received medical treatment, and to identify patient factors
that influenced decision-making for surgical or medical management.
Animals: Thirty-eight dogs with cholelithiasis identified on abdominal ultrasonogra-
phy (AUS).
Methods: Medical records of dogs with cholelithiasis on AUS between 2010 and
2019 were retrospectively reviewed. Cases were classified as symptomatic (n = 18)
or incidental (n = 20) and divided into medically treated (n = 13), surgically treated
(n = 10), and no treatment (n = 15) groups. Biochemical variables and cholelith loca-
tion were compared between symptomatic and incidental groups using Mann-
Whitney U and chi-squared tests, respectively. Survival times were compared using
Kaplan-Meier survival analysis.
Results: Symptomatic cases had higher alkaline phosphatase (P = .03), gamma-
glutamyl transferase (P = .03), and alanine transferase (P = .02) activities than did
incidental cases. A higher proportion of symptomatic cases (44.4%) had chole-
docholithiasis than did incidental cases (0%; P = .003). Seventy percent of surgically
managed dogs, 7.7% of medically managed dogs, and 0% of nontreated dogs had
choledocholiths at presentation. Seventeen dogs had follow-up AUS: cholelithiasis
completely resolved in 4/8 medically treated, 5/7 of surgically treated, and 1/2 non-
treated dogs. Median survival time was 457.4 days, with no significant difference
between incidental and symptomatic dogs.
Conclusions and Clinical Importance: Medical treatment can be effective for man-
agement of cholelithiasis in dogs, with clinical presentation and cholelith location
playing important roles in treatment decision-making.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUS, abdominal ultrasonography; CBD, common bile duct; EHBDO, extrahepatic
biliary duct obstruction; GGT, γ-glutamyl transferase; UDCA, ursodeoxycholic acid.
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1 | INTRODUCTION
Cholelithiasis is an uncommon condition in dogs, with a recent study
identifying a prevalence of 0.97%.1 Geriatric, female, small breed dogs
are overrepresented in studies of cholelithiasis in dogs.2-4 Clinical
signs are often nonspecific and include abdominal pain, vomiting,
anorexia, icterus, polyuria, and polydipsia, but the frequency of symp-
tomatic cholelithiasis is low1,2,5,6 with 1 study reporting 13.1% of dogs
to be symptomatic. Ursodeoxycholic acid (UDCA) is a synthetic hydro-
philic bile acid that minimizes hepatocellular and oxidative damage
resulting from bile acid retention in the liver by displacing hydropho-
bic bile acids. It also has choleretic and anti-inflammatory actions in
the gallbladder.7-9 It is used commonly in people for medical dissolu-
tion and prevention of cholelithiasis,8,10,11 but only a single case
report documents dissolution of choleliths in a dog treated with
UDCA.5
Few previous descriptive studies of medical management of cho-
lelithiasis in dogs are available, resulting in limited evidence from
which to base treatment decisions on.1,2 Additional studies in dogs
are needed to develop a consensus for treatment.
The aims of our retrospective study were to describe outcomes of
medically and surgically managed dogs and to identify patient factors
that influence decision-making for surgical or medical management.
2 | MATERIALS AND METHODS
The medical records of dogs diagnosed with cholelithiasis from 2010
to 2019 at The Queen's Veterinary School Hospital, University of
Cambridge were retrospectively evaluated. Cases were identified by
searches of the Hospital's imaging database for key word tags (liver—
gb stones, cholelith, gallstones) to identify imaging reports in which
cholelithiasis was described. Data collected included signalment (sex,
neuter status, age), clinical signs, physical examination findings, clinical
pathology data (including results of CBC [Sysmex XT-2000iV auto-
mated hematology analyzer; Sysmex XN-1000 automated hematology
analyzer, Sysmex Corporation, Kobe, Japan] and blood biochemistry
[Olympus AU400 chemistry analyzer; Olympus AU480 chemistry ana-
lyzer, Olympus, Tokyo, Japan]), abdominal ultrasonography (AUS) find-
ings, results of liver and gallbladder histopathology, bile cytology, bile
culture, treatment, and outcome (including follow-up AUS and bio-
chemistry results). The reference intervals for all assessed CBC and
blood biochemistry values are identical between respective CBC and
biochemistry analyzers; therefore, results are presented as values
rather than multiples of upper reference limits. Inclusion criteria
required an ultrasonographic diagnosis of cholelithiasis consistent
with published criteria.12 Dogs with incomplete or absent medical
records were excluded. Medical records were considered incomplete
when no clinical records or imaging reports from the time of diagnosis
were available for analysis. Follow-up information was obtained in
35 cases by contacting the registered owner to ask about outcome
and for permission to contact their primary care practice for clinical
records. The study was approved by the Ethics and Welfare commit-
tee of the Department of Veterinary Medicine, University of Cam-
bridge, reference CR435.
Ultrasound examinations were performed in all cases by board-
certified radiologists or under their supervision. Ultrasonography was
performed in all cases using either a Philips HDI 5000 (Philips, Eindho-
ven, the Netherlands), Philips EPIQ 7 (Philips), or Esaote MyLab Eight
XP (Esaote, Genoa, Italy) machine.
Follow-up biochemistry was performed at variable time points,
and therefore data were categorized into 6 time intervals after pre-
sentation: 0.5 to 1 months, 1 to 3 months, 3 to 6 months, 6 to
12 months, 12 to 24 months, and >24 months.
Presence of concurrent endocrinopathies was recorded. Cases
were diagnosed either before referral or during investigations at the
investigators' institution. Dogs were considered to have hyperad-
renocorticism if an ACTH stimulation test or low-dose dexametha-
sone suppression test was positive along with compatible clinical
signs. Dogs were considered to have hypothyroidism if a historical
diagnosis (with consistent serum total thyroxine and thyroid stimulat-
ing hormone concentrations) had been made before referral. Dogs
were considered to have primary hyperparathyroidism when ionized
hypercalcemia was present with increased parathyroid hormone con-
centration and a parathyroid mass visible on ultrasound examinations
and other causes of hypercalcemia had been ruled out during clinical
investigations at the investigators' institution. Dogs were considered
to have diabetes mellitus when presented with fasting hyperglycemia,
in combination with glucosuria and compatible clinical signs.
Cases were subdivided into symptomatic and incidental cholelithia-
sis. Dogs were classified as symptomatic if they had clinical signs attrib-
utable to cholelithiasis (eg, vomiting, abdominal pain, inappetence,
lethargy, icterus), ultrasonographic abnormalities of the gallbladder or
biliary tree (increased gallbladder wall thickness or echogenicity, com-
mon bile duct [CBD] dilatation, cystic duct dilatation), and blood bio-
chemistry abnormalities consistent with cholelithiasis (increases in
hepatobiliary variables, cholesterol, or bilirubin)1,3,5 and when no alter-
native disease process could account for the clinical presentation. Cases
were classified as incidental when their clinical signs were not attribut-
able to cholelithiasis, with ultrasonographic evidence of an otherwise
normal biliary tract and no biochemical abnormalities attributable to
cholelithiasis, or when clinical signs and biochemical abnormalities could
be attributed to another disease process. Criteria were modeled on a
recent study of cholelithiasis in dogs.1
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Cases also were divided into 3 treatment categories: surgical,
medical, and no treatment. Cases included in the surgical group under-
went surgical intervention for cholelithiasis, cases in the medical
group all received UDCA (Destolit, Norgine, UK) without surgical
intervention for cholelithiasis, and cases in the no treatment group did
not receive any specific treatment for cholelithiasis. One case
reported here also has been described in a case report, whereas the
remainder has not been reported previously.5
2.1 | Statistical analysis
Categorical data were anonymized and recorded, with each category
presented descriptively. Continuous data (including age in years, CBC
and blood biochemistry results, treatment doses and duration) were
recorded and values for median and range were calculated for each
variable.
Because both groups consisted of ≤20 cases, nonparametric
2-tailed Mann-Whitney U tests were performed to compare age, CBC,
and blood biochemistry variables between symptomatic and incidental
groups. Proportions of dogs with choledocholiths were compared
between symptomatic and incidental groups using Chi-squared tests
with Yates correction. Data regarding location, number, and radio-
pacity of choleliths, breed, and neuter status were presented
descriptively.
Age, breed and neuter status, CBC and biochemistry results,
treatment doses and duration, location and number of choleliths,
radiopacity of choleliths, and ultrasonographic progression of choleli-
thiasis at follow-up for each treatment group were presented
descriptively.
The Kaplan-Meier method was used to calculate survival curves
from observed survival times and a log rank test was performed to
determine if differences in survival distribution existed between
symptomatic and incidental cases. All statistical analyses were per-
formed using SPSS version 26 and Graphpad QuickCalcs. Results
were considered significant if P < .05.
3 | RESULTS
3.1 | Signalment
Cholelithiasis was identified in 38 dogs. These included 22 breeds and
2 mixed-breed dogs. Cavalier King Charles Spaniels (CKCS; 10.5%, n = 4)
were the most commonly identified breed, followed by Dachshunds
(7.9%, n = 3), Jack Russell Terriers (7.9%, n = 3), Labradors (7.9%, n = 3),
Cocker Spaniels (5.2%, n = 2), Miniature Schnauzers (5.2%, n = 2), Whip-
pets (5.2%, n= 2), and Yorkshire Terriers (5.2%, n = 2).
Sex and neuter status were recorded in all cases. There were
14 neutered males, 13 neutered females, 6 intact males, and 5 intact
females. Median age at diagnosis was 9.54 years (range,
0.25-12 years).
3.2 | Clinical presentation
Eighteen dogs (47.4%) had symptomatic cholelithiasis, and 20 cases
(52.6%) were classified as incidental. The median age at presentation
of dogs with incidental cholelithiasis (10.4 years) was significantly
higher than that of dogs with symptomatic cholelithiasis
(8.75 years; P = .01).
Clinical signs of symptomatic dogs are presented in Table 1. The
primary disease processes of dogs with incidental cholelithiasis were
neoplasia (n = 8), other hepatobiliary (n = 3), endocrine (n = 3), auto-
immune (n = 2), neurological (n = 2), gastrointestinal (n = 1), and
reproductive (n = 1). Three dogs with incidental cholelithiasis had
concurrent endocrinopathies that were not the primary presenting
complaint.
3.3 | Concurrent endocrinopathy
Eight dogs were presented with concurrent endocrinopathies. Two
dogs had symptomatic cholelithiasis and concurrent endocrinopathies:




Clinical signs reported in dogs presenting with
symptomatic cholelithiasis (n = 18)
Vomiting 13 72.2%




Abdominal pain 4 22.2%
Weight loss 3 16.7%
Polyuria/Polydipsia 1 5.6%
Pollakiuria, stranguria, hematuria, nocturia 1 5.6%
Thinning of haircoat 1 5.6%
Deafness 1 5.6%
Shifting lameness 1 5.6%
ALLAN ET AL. 3
primary hyperparathyroidism (n = 1) and hypothyroidism (n = 1). The
remaining 6 dogs had incidental cholelithiasis and hyper-
adrenocorticism (n = 3), primary hyperparathyroidism (n = 1), and dia-
betes mellitus (n = 2).
3.4 | Clinical pathology
Results of CBC at presentation were available for 35 dogs. No signifi-
cant differences in hematological variables (Table 2) were found
between symptomatic and incidental groups.
Blood biochemistry results at presentation were available for
37 dogs (Table 3). Activities of alkaline phosphatase (ALP; P = .03),
γ-glutamyl transferase (GGT; P = .03), and alanine aminotransferase
(ALT; P = .02) were significantly higher in symptomatic cases than in
incidental cases. No significant differences were found in bilirubin or
cholesterol concentrations or aspartate aminotransferase (AST) activ-
ity between symptomatic and incidental groups.
3.5 | Diagnostic imaging
Imaging findings are summarized in Table 4. In the incidental group,
choleliths were reported solely within the gallbladder in 19/20 (95%)
cases, no dogs in the incidental group had choledocholithiasis. A signifi-
cantly higher proportion of symptomatic dogs (44.4%) had
choledocholiths than incidental dogs (0%; X2 = 8.744, df = 1, P = .003).
Seven of 10 (70%) surgically managed dogs, 1/13 (7.7%) medically man-
aged dogs, and 0/15 (0%) nontreated dogs had choledocholiths.
Abdominal radiography was performed in 22 dogs. Five dogs had
evidence of mineral density and 17 dogs had radiolucent cholelithiasis
(Table 4). Both dogs with primary hyperparathyroidism had radi-
opaque choleliths.
3.6 | Treatment groups
Ten dogs (26.3%) underwent surgical management for cholelithiasis,
13 dogs (34.2%) were medically treated using UDCA, and 15 dogs
(39.5%) received no specific treatment.
3.7 | Surgical management
All surgically treated dogs were symptomatic for cholelithiasis. The
median age was 9.33 years (range, 4.5-11.0 years).
Nine dogs underwent cholecystectomy, with additional
choledochotomy (n = 1), duodenotomy (n = 2), choledocholithotomy
and duodenotomy (n = 1), duodenotomy and sphincterotomy (n = 1)
and choledochotomy and duodenostomy (n = 1), and 1 dog under-
went solely duodenotomy to place a biliary stent (Figure 1). Cholelith
composition was not determined in these cases.
Two dogs were managed using UDCA for 43 days and 72 days,
respectively, before surgery and before developing gallbladder
rupture and extrahepatic biliary duct obstruction (EHBDO),
respectively.
Liver histopathology results were available for 9 dogs, of which 8 had

















































































to place a 
biliary stent 




























alone (n = 1)
Died post-
operavely
F IGURE 1 A diagram illustrating the outcomes of dogs in the surgical treatment group. AUS, abdominal ultrasonography; d, days; EHBDO,
extrahepatic biliary duct obstruction; GB, gall bladder
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Bile culture results were available for 3 dogs and all cultures
yielded multiple organisms, with positive cultures for Escherichia coli
(n = 2), Enterococcus spp. (n = 3), and coliform species (n = 1).
Nine dogs survived to discharge and all were treated using a
median dose of 11.9 mg/kg/d (range, 8.9-14.4 mg/kg/d) UDCA
postoperatively for a median duration of 128.5 days (range,
25-1990 days). Three dogs were treated using S-adenosylmethionine
(SAMe)/Silybin (Denamarin, Protexin, UK) postoperatively at a median
dose of 16 mg/kg/d (range, 11.9-37.7 mg/kg/d) and median duration
of 14 days (range, 14-28 days). Additional postoperative medications
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Note: The column labeled “P” indicates the P values from Mann-Whitney U test analysis of the symptomatic and incidental groups.
Abbreviation: WBC, total white blood cell count.
TABLE 3 Blood biochemistry values at presentation, range is in brackets
Measurement
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Note: The column labeled “P (MW)” indicates the P values from Mann-Whitney U test analysis of the symptomatic and incidental groups.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase.
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consisted of potentiated amoxicillin (n = 4), cephalexin (n = 2),
marbofloxacin (n = 2), tramadol (n = 3), carprofen (n = 1), paraceta-
mol/codeine (n = 1), PO potassium gluconate (n = 1), and omepra-
zole (n = 1).
3.8 | Medical management
Medically managed dogs were presented at a median age of 8.58 years
(range, 0.25-11.7 years). Eight dogs (61.5%) were symptomatic for cho-
lelithiasis and 5 (38.5%) were incidental cases. The median dose of
UCDA administered was 11.7 mg/kg/d (range, 6.28-41.1 mg/kg/d) with
a median duration of administration of 91 days (range, 30-1642 days).
Five dogs were treated concurrently with SAMe/Silybin at a median
dose of 19.1 mg/kg/d (range, 17.9-29.4 mg/kg/d) and 7 dogs were
treated concurrently using antibiotics, consisting of potentiated amoxi-
cillin (n = 4), amoxicillin (n = 1), potentiated amoxicillin and
marbofloxacin (n = 1), and metronidazole (n = 1).
Liver biopsy histopathology results were available for 2 dogs
(Table S1).
Bile cytology results were available for 1 dog and disclosed septic
neutrophilic cholecystitis with gram-positive bacilli.
3.9 | No treatment
Fifteen dogs received no specific treatment for cholelithiasis and all
were incidental cases. The primary disease processes were neoplasia
(n = 8), autoimmune (n = 2), neurological (n = 2), hepatobiliary
(n = 1), endocrine (n = 1), and reproductive (n = 1). The median age
was 10.83 years (range, 7.25-12.0 years). Histopathology results were
available for one dog (Table S1).
3.10 | Outcomes
3.10.1 | Surgical management outcome
Follow-up biochemistry results were available for 7 dogs with a
median final follow-up time of 193 days (range, 27-1463 days;
Table 5). Follow-up AUS was performed in 7 surgically managed dogs
with a median time from presentation to final AUS of 325 days (range,
12-1461 days; Table 6). Five of seven (71.4%) dogs with imaging
follow-up experienced complete resolution of cholelithiasis, and 2/7
(29.6%) did not have complete resolution.
Three dogs were alive at the time of writing, 6 were dead, and
1 was lost to follow-up (Figure 1). Median survival time was 577 days
(range, 0-2266 days). One dog underwent repeat surgery to place a bili-
ary stent 198 days after initial cholecystectomy because of lack of clinical
improvement and persistently increased liver enzyme activities,
suspected to be caused by chronic scarring of the sphincter, resulting in
chronic biliary tract obstruction. Complete resolution of cholelithiasis was
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One dog with primary hyperparathyroidism that underwent cho-
lecystectomy had evidence of recurrent choledocholithiasis at 41 days
postsurgery and subsequently was treated using UDCA without recur-
rence of symptomatic cholelithiasis and was euthanized 577 days
after presentation for causes unrelated to cholelithiasis.
The single dog with a decrease in cholelith number at final imag-
ing follow-up was presented initially with multiple cholecystoliths,
choledocholiths, and choleliths within the intrahepatic ducts, and the
presence of a single cholelith within the intrahepatic ducts was docu-
mented at follow-up 892 days postoperatively.
All 5 dogs that survived to discharge and that were dead at the
time of writing were euthanized because of, or died of, disease
unrelated to cholelithiasis.
3.10.2 | Medical management outcome
Follow-up biochemistry results were available for 10 dogs with a
median follow-up time of 67.5 days (range, 29-833 days; Table 5).
Follow-up AUS was performed in 8 dogs with a median time from pre-
sentation to final AUS of 79 days (range, 37-833 days; Table 6). Fifty
percent of medically managed dogs with repeat AUS had complete
resolution of cholelithiasis and 12.5% had a decrease in cholelith
number.
Four dogs were alive at the time of writing, 8 were dead, and
1 was lost to follow-up (Figure 2). Median survival time was
498.5 days (range, 56-2457 days).
Recurrence of clinical signs that could be attributable to choleli-
thiasis was seen in 1 symptomatic dog with multiple cholecystoliths
after 314 days, which improved with PO antibiotic and IV fluid treat-
ment, but repeat AUS was not performed.
Of 3 dogs that died with signs of hepatobiliary disease, 1 was
diagnosed with multiple acquired portosystemic shunts and had no
evidence of cholelithiasis at final imaging follow-up 64 days before
death and another underwent necropsy (Table S1) at which no
choleliths were noted. The final dog was presented with weight loss
and icterus and euthanized 158 days after detection of cholelithiasis
because of suspicion of necrotizing pancreatitis or pancreatic
TABLE 6 Progression of cholelithiasis from presentation to follow-up of dogs with subsequent abdominal ultrasonography examinations after




size or number Static
Increase in cholelith
size or number Recurrent
Median duration of imaging












50% (n = 1) 0 50% (n = 1) 0 n/a 159.5 (81-238)
aThis patient underwent cholecystectomy, cystotomy, and partial cystectomy. At presentation, multiple choleliths were present in the gallbladder and a
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F IGURE 2 A diagram illustrating the outcomes of dogs in the medical treatment group. AUS, abdominal ultrasonography
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neoplasia, but necropsy was not performed. No evidence was found
that ongoing cholelithiasis in this subset of patients directly contrib-
uted to death.
3.10.3 | Outcome of nontreatment group
Follow-up biochemistry results were available for 6 dogs with a median
final follow-up time of 85.5 days (range, 3-461 days; Table 5). Follow-up
AUS was performed in 2 dogs with a median time from presentation to
final AUS of 160 days (range, 81-238 days; Table 6). One dog with repeat
AUS had complete resolution of cholelithiasis. Six dogs were alive, 8 were
dead, and 1 was lost to follow-up (Figure 3). Median survival time was
399.5 days (range, 3-2191 days). One dog died with signs of hepatobiliary
disease, having been presented with hepatocellular carcinoma, and was
euthanized 10 days after cholelith detection because of development of
neurological signs. No dogs were reported to have either developed or
died with clinical signs attributable to cholelithiasis.
3.11 | Survival
Median survival time of all dogs was 457.4 days (range, 0-2457 days).
Four symptomatic dogs were alive at the time of writing, 12 had died,
and 2 were lost to follow-up. The median survival time of symptomatic
cases was 498 days (range, 0-2457 days). Nine dogs in the incidental
group were alive at the time of writing and 11 had died, but the cause
and time of death in 1 dog was unknown. The median survival time of
dogs in the incidental group was 434 days (range, 3-2191 days). No sig-
nificant difference was found in survival distribution between the symp-
tomatic and incidental groups (X2 = 0.044, df = 1, P = .83; Figure 4).
4 | DISCUSSION
Previous reports of medical management of cholelithiasis in dogs have
documented persistence of cholelithiasis despite clinical
improvement.1-3,6 In contrast to choleliths in humans, which are pri-
marily cholesterol-based, choleliths in dogs usually are composed of
calcium carbonate, cholesterol, and bilirubin.4 Ursodeoxycholic acid
commonly is utilized in the management of some affected humans,
but surgery usually is recommended for symptomatic patients.13 Liter-
ature describing use of UDCA in dogs with cholelithiasis is
limited,1,2,5,6 and no published guidelines guide treatment in veteri-
nary medicine, as compared to human medicine.13 In the absence of
such guidelines, factors that appeared to influence treatment choice
included clinical presentation, cholelith location, and hepatobiliary
enzyme activities.
Similar to previous reports, older, small-breed dogs were overrep-
resented in our study with a high prevalence in CKCS.2,4,14 We did
not identify a significant sex predisposition, similar to a previous
study.1 These findings contrast with those in the human medical liter-
ature where females have a higher incidence of cholelithiasis,
suspected to be associated with the effects of estrogen to enhance
cholesterol synthesis and decrease bile acid synthesis.11,15-19 This
effect likely does not influence the pathophysiology in dogs because
they commonly are neutered, and cholelith composition differs from
that in humans.4
Interestingly, 8 dogs were presented with concurrent endocrino-
pathies, with 1 surgically treated dog with primary hyperparathyroid-
ism developing cholelith recurrence. Both hyperparathyroid dogs had
radiopaque choleliths, and therefore it is reasonable to assume hyper-
calcemia could have contributed to development of cholelithiasis in
these dogs. This conclusion is supported by the fact that humans with
cholelithiasis have an increased incidence of hypercalcemia20 and pre-
vious reports that analyzed cholelith composition in dogs found cal-
cium to be a major component.2,21 Although debate exists as to
whether an association between hyperparathyroidism and cholelithia-
sis occurs in humans, 3 studies have reported an increased incidence
of hyperparathyroidism,20,22,23 but this relationship has not been
investigated in dogs. Hypercholesterolemia associated with endocri-
nopathies such as hyperadrenocorticism or hypothyroidism could
have predisposed dogs in our study to develop cholelithiasis, given
that hyperlipidemia, hypothyroidism, and hyperadrenocorticism have
Not treated (n = 15)
Underwent repeat 
AUS (n = 2)
Complete 
resoluon (n = 1)
Died of disease 
unrelated to 
cholelithiasis
Stac (n = 1)
Lost to follow-up 
aer this




clinical signs of 
cholelithiasis (n = 6) 
Deceased (n= 7)
Neoplasia (n = 3) Dog aack (n = 1) Euthanasia due to seizures (n = 1)
Euthanasia as 




F IGURE 3 A diagram illustrating the outcomes of the dogs in the nontreatment group. AUS, abdominal ultrasonography
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been found in some studies to be associated with the presence of gall-
bladder mucoceles.24,25 Given the well-known associations between
endocrinopathies and gallbladder dysfunction,25 we recommend that
future research be performed to investigate incidence rates of choleli-
thiasis in dogs with concurrent metabolic and endocrine diseases.
A novel finding of our study is that symptomatic dogs were signif-
icantly younger than dogs in the incidental group. Similarly, in the
human medical literature, younger age is a factor associated with
symptomatic cholelithiasis.16,17 Age therefore should be considered
when assessing dogs with cholelithiasis because younger dogs in our
study appeared more likely to have symptomatic cholelithiasis. Almost
50% of dogs in our study were considered symptomatic, contrasting
with previously published findings of just 13.1%.1 In the human and
veterinary medical literature, most cases of cholelithiasis are reported
to be incidental,1,2,6,11,16,17 with clinical signs often seen with concur-
rent cholecystitis, associated with biliary obstruction or gallbladder
rupture.3,5 The most frequently identified clinical signs in symptomatic
dogs in our study were vomiting, decreased appetite, lethargy, diar-
rhea, icterus, and abdominal pain, similar to previous reports.1,6
Although symptomatic dogs in our study had higher ALP, ALT,
and γ-glutamyltransferase (GGT) activities than did incidental dogs,
we failed to detect significant differences in AST activity, or bilirubin
or cholesterol concentrations. This observation contrasts with the
findings of a previous study1 that documented significant increases
in AST, ALT, and GGT activity, and bilirubin and cholesterol concen-
trations in symptomatic dogs. Failure to detect significant differ-
ences in bilirubin and cholesterol concentrations and AST activity in
our study may have been a consequence of the small number of
dogs in the incidental group. Our findings and those of the
aforementioned study suggest some correlation between biochemis-
try abnormalities and the symptomatic status of patients with chole-
lithiasis, and therefore dogs with cholelithiasis and associated
biochemical abnormalities warrant careful evaluation. It is important,
however, to be aware that nonspecific blood biochemistry changes
have been reported in dogs with ultrasonographic evidence of
apparent biliary obstruction.5
Choleliths were identified within the gallbladder in 92.1% of
cases, a proportion similar to the previously reported 94%.1 The
important findings that 100% of the nontreatment group and 95% of
the incidental group had cholecystolithiasis alone could indicate that
the presence of choleliths, in the absence of gallbladder wall abnor-
malities and CBD dilatation, may not be associated with clinical signs.
However, 1 surgically managed dog with cholecystolithiasis required
surgical intervention because of gallbladder rupture. An interesting
aspect of our study is that all dogs observed to have choledocholiths
were symptomatic. This finding may be related not only to bile duct
obstruction but also to the fact the CBD is well-innervated26 and
obstruction caused by choledocholithiasis likely is painful. This consid-
eration combined with the important finding that a high proportion of
surgically treated dogs had choledocholithiasis, suggests that cholelith
location plays an important role in determining treatment modality.
The only dog with choledocholithiasis without surgical intervention
had a single choledocholith that was not causing complete EHBDO
and had unremarkable serum biochemical changes other than mild
hypercholesterolemia. Therefore, medical management was deemed a
reasonable option, and was successful in this case.5 Further research
is required to determine which factors should influence the decision
to intervene with surgical vs medical management.
F IGURE 4 A Kaplan-Meier curve comparing survival times between dog clinically affected by cholelithiasis and dogs with incidentally
detected cholelithiasis. Censored indicates that an event (death) did not occur in the time the dog has been followed up
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All surgically managed dogs were symptomatic for cholelithiasis
and a large proportion were documented to have choledocholiths.
The median results of ALP, GGT, ALT, and AST activities and bilirubin
concentration in this cohort were markedly increased above reference
intervals, which offer insight into historical treatment decision-making
and suggest that biochemistry results may have influenced treatment
choice in this cohort. However, because of the retrospective nature of
our study and lack of statistical comparison with a control group we
can only speculate. Despite the risk of postoperative morbidity and
mortality, long-term prognosis appeared to be favorable in surgically
treated dogs, with complete resolution of cholelithiasis in 5 of 7 dogs
with follow-up AUS. Both cases without complete resolution of chole-
lithiasis on AUS remained asymptomatic postoperatively and died of
causes unrelated to cholelithiasis. Although previously published data
suggests that dogs undergoing cholecystectomy have better out-
comes than medically treated dogs,3 further research is required to
establish conclusive evidence of superiority.
Four medically treated dogs in our study had resolution of choleli-
thiasis at follow-up AUS, and a single dog had a decrease in cholelith
number. This finding has not been reported in the literature describing
use of UDCA in dogs with cholelithiasis,1-3 other than the single case
included in a previous study.5 Interestingly, 2 dogs with complete res-
olution had radiolucent choleliths, indicating calcium was not a major
component of these choleliths, but no cases had composition analysis
performed, representing a limitation of our study. In human medicine,
clear guidelines and inclusion criteria exist to determine which
patients with cholelithiasis are likely to benefit from treatment using
UDCA, with success rates varying from 60% to 90%.27 However, no
guidelines exist in veterinary medicine, and despite widespread use of
UDCA in veterinary medicine for the treatment of hepatobiliary
disease,28,29 only 2 case reports documenting its efficacy exist.5,7
Ursodeoxycholic acid is a potent cholerectic,9 and resolution of chole-
lithiasis could be accounted for by passing of choleliths because of
the cholerectic action of UDCA rather than litholysis. It also cannot
be discounted that when decreases in cholelith size or number were
seen, smaller choleliths could have passed, and new, smaller
choleliths subsequently could have formed and be misinterpreted as
a decrease in size or partial dissolution of the previous cholelith.
Despite this, our findings suggest UDCA can be safely used in the
medical management of some dogs, which should inform future pro-
spective studies investigating the use of UDCA for management of
cholelithiasis in dogs.
Medical management was not effective in all cases. In 3 dogs,
cholelithiasis did not resolve, although 2 had an improvement in clini-
cal signs and the third was euthanized because of development of
suspected histiocytic sarcoma 56 days after detection of cholelithiasis.
Two surgically managed dogs were treated with UDCA for 43 days
and 72 days before surgery and before developing gallbladder rupture
and EHBDO, respectively, highlighting the importance of careful case
selection and vigilant monitoring. Because of the retrospective nature
of our study, it is not possible to predict which cases will respond to
medical management, and future research should focus on identifying
factors influencing this outcome.
Dogs in the nontreatment group all had choleliths solely within
the gallbladder, were asymptomatic, and had lower median
hepatobiliary laboratory test results at presentation than did both
other treatment groups. None of the dogs progressed to require surgi-
cal or medical intervention or was reported to have died of causes
attributable to cholelithiasis. The favorable survival time of the non-
treatment group indicates that the decision not to treat cholelithiasis
was not detrimental. It is reasonable to conclude from the findings of
our study and previous studies1,2 that dogs with choleliths in the gall-
bladder only, without clinical signs attributable to cholelithiasis
(or clinical signs attributable to another disease process), with rela-
tively normal serum biochemical findings and without ultrasono-
graphic evidence of changes to the gallbladder wall, cystic duct, or
CBD are unlikely to progress to require intervention, given that
untreated cases were followed for a median of 399.5 days (range,
3-2191 days) without requiring intervention. A proportion (3%) of
asymptomatic dogs, however, may go on to become symptomatic
when untreated,1 and cholelithiasis always carries a risk of progres-
sion from clinically silent to clinically relevant. Given the paucity of lit-
erature in veterinary medicine, it is impossible to accurately predict
which, if any, of these patients eventually will become symptomatic or
require treatment, and further research should be performed to iden-
tify patient factors that increase the risk of clinical events.
Our study had some limitations. First, its retrospective nature
meant that only incomplete data were available in some cases, with
variations in clinical evaluation, case management, and timing of
follow-up. Patients in the medically treated group did not have consis-
tent treatment plans, with variations in daily dose, dosing regimen,
and duration of treatment with UDCA, along with a variety of addi-
tional drugs and concurrent diseases. It is possible that dose, fre-
quency, or duration of administration of UDCA could affect cholelith
progression, and future prospective studies should aim to determine if
protocols differ in efficacy. The lack of a control group with which to
compare progression of cholelithiasis represents another limitation,
and it cannot be proven that UDCA affected progression of cholelithi-
asis or whether this finding is a result of a type II error. Nevertheless,
our study has shown UDCA can be safely used in the treatment of
dogs with cholelithiasis. Future research should include a randomized
placebo-controlled prospective study to assess the efficacy of UDCA
in cholelithiasis patients. Another limitation is that information regard-
ing liver and gallbladder histopathology, bile cytology, and culture was
not available for all cases because of the retrospective nature of the
study. The possibility that underlying liver or gallbladder pathology
may have contributed to development of cholelithiasis and outcome
in these cases exists, with histopathological evidence of concurrent
cholangiohepatitis and cholecystitis reported in cats and dogs with
cholelithiasis1,2,30 and with chronic cholecystitis identified in the
majority of dogs for which histopathology results were available in
our study. Diet is a factor that may influence progression of cholelithi-
asis and was not investigated in our study. Information regarding diet
type, caloric intake, feeding patterns, and habits was not available in
sufficient detail because of the retrospective nature of our study. In
human medicine, diet is an important factor in the management of
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cholelithiasis,10 with low-cholesterol diets often recommended. Diet
may have played a role in the development of cholelithiasis in some of
our patients, and a change in diet could have contributed to improve-
ment of cholelithiasis, but this remains unknown. Also, cholelith size
was not routinely recorded in our study, and therefore analysis of
cholelith size in relation to clinical presentation, treatment modality,
and outcome could not be performed. Cholelith size may be important
given that in human medicine the presence of choleliths >10 mm is
associated with a higher risk of clinical events17 and choleliths <5 mm
respond most effectively to UDCA.10,11,27
A further limitation of our study and of previous studies investi-
gating medical management of cholelithiasis is that composition analy-
sis is rarely performed, with cholelith composition being a major
factor affecting efficacy of UDCA in management of cholelithiasis in
humans. Despite the lack of composition analysis in our study, 77% of
dogs in which abdominal radiography was performed had radiolucent
choleliths. This finding indicates that cholelith composition was not
purely calcium-based31,32 in the majority of these dogs, and instead it
is possible that cholesterol-based choleliths were more prevalent.
It is also possible that the cholerectic action of UDCA aids passing
of choleliths, in which case composition would be less important. This
possibility may contribute to the variation in results between our
study in which apparent dissolution of choleliths was observed and in
previous studies where cholelithiasis was persistent.1,2 A final limita-
tion of our study is that complete follow-up was not available for
every case, with 3 cases lost to follow-up and only 2 nontreated cases
undergoing repeat AUS. Therefore, it is possible that important data
were not acquired that may have influenced our findings.
In conclusion, we documented resolution or improvement of cho-
lelithiasis in several dogs treated with UDCA. This finding suggests
that, with careful case selection, UDCA may be a safe and effective
tool for management of cholelithiasis in dogs. Our study suggests that
patients presenting with marked increases in ALP, ALT, and GGT
activity with or without ultrasonographic evidence of choledocholiths
and with or without symptomatic cholelithiasis can be considered for
surgical intervention, whereas medical management should be consid-
ered in patients without choledocholithiasis. Future prospective stud-
ies are required to develop management guidelines similar to those
used in human medicine. Development of evidence-based guidelines
for management of cholelithiasis in dogs would enable improved out-
comes for patients and offer more reliable prognoses for clinicians,
especially given the lack of consensus regarding medical management
of cholelithiasis in dogs.
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